Abstract
Although increasing evidence supports therapeutic modulation of NMDA pathways to treat symptoms of breathlessness in COPD,
d
-cycloserine does not demonstrate sufficient efficacy to be considered for phase 3 trials in pulmonary rehabilitation
https://bit.ly/3Wm64ni